ArticleCurrent oncology (Toronto, Ont.)2022

Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.

Kamrunnahar Shanta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.